TY - JOUR
T1 - Postoperative Adjuvant Chemotherapy With Fluorouracil, Doxorubicin, Cyclophosphamide, and BCG Vaccine
T2 - A Follow-up Report
AU - Buzdar, Aman U.
AU - Blumenschein, George R.
AU - Tashima, Charles K.
AU - Hortobagyi, Gabriel N.
AU - Gutterman, Jordan U.
AU - Hersh, Evan M.
AU - Freireich, Emil
AU - Smith, Terry L.
AU - Gehan, Edmund A.
AU - Campos, Luis T.
AU - Wheeler, Warren L.
PY - 1979/10/5
Y1 - 1979/10/5
N2 - Two hundred twenty-two patients with stage II or III breast cancer following regional therapy were treated with a combination of fluorouracil, doxorubicin hydrochloride (Adriamycin), cyclophosphamide, and BCG vaccine. At 54 months of study (median follow-up, 30 months), the estimated proportions remaining disease-free two and three years after surgery were 83% and 78%, respectively, in the chemotherapy group and 64% and 55%, respectively, in 151 historical control patients. Estimated two- and three-year survival rates were 93% and 89%, respectively, in the chemotherapy group and 84% and 58%, respectively, in the control patients. Congestive heart failure has developed in three patients, possibly related to the use of doxorubicin. Adjuvant chemotherapy with these drugs was effective in prolonging the disease-free interval and survival of patients irrespective of menopausal status, degree of nodal involvement, or stage of the disease. (JAMA 242:1509-1513, 1979).
AB - Two hundred twenty-two patients with stage II or III breast cancer following regional therapy were treated with a combination of fluorouracil, doxorubicin hydrochloride (Adriamycin), cyclophosphamide, and BCG vaccine. At 54 months of study (median follow-up, 30 months), the estimated proportions remaining disease-free two and three years after surgery were 83% and 78%, respectively, in the chemotherapy group and 64% and 55%, respectively, in 151 historical control patients. Estimated two- and three-year survival rates were 93% and 89%, respectively, in the chemotherapy group and 84% and 58%, respectively, in the control patients. Congestive heart failure has developed in three patients, possibly related to the use of doxorubicin. Adjuvant chemotherapy with these drugs was effective in prolonging the disease-free interval and survival of patients irrespective of menopausal status, degree of nodal involvement, or stage of the disease. (JAMA 242:1509-1513, 1979).
UR - http://www.scopus.com/inward/record.url?scp=84944965619&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84944965619&partnerID=8YFLogxK
U2 - 10.1001/jama.1979.03300140025017
DO - 10.1001/jama.1979.03300140025017
M3 - Article
C2 - 470088
AN - SCOPUS:84944965619
SN - 0098-7484
VL - 242
SP - 1509
EP - 1513
JO - JAMA: The Journal of the American Medical Association
JF - JAMA: The Journal of the American Medical Association
IS - 14
ER -